Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.32 USD | 0.00% | +6.45% | +133.63% |
Summary
- On the basis of various fundamental qualitative criteria, the company appears to be particularly poorly ranked from a medium and long-term investment perspective.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The group usually releases upbeat results with huge surprise rates.
Weaknesses
- According to Standard & Poor's' forecast, revenue growth prospects are expected to be very low for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- The company appears highly valued given the size of its balance sheet.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- Revenue estimates are regularly revised downwards for the current and coming years.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The appreciation potential seems limited due to the average target prices set by the analysts covering the stock.
- Over the past four months, analysts' average price target has been revised downwards significantly.
- The average consensus view of analysts covering the stock has deteriorated over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+133.63% | 242M | C | ||
+25.83% | 661B | C+ | ||
+27.00% | 566B | B | ||
-6.76% | 352B | C+ | ||
+20.34% | 332B | B- | ||
+3.00% | 283B | C+ | ||
+13.09% | 231B | B+ | ||
+5.46% | 200B | B- | ||
-9.61% | 195B | A+ | ||
-6.26% | 145B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- NKTR Stock
- Ratings Nektar Therapeutics